Ferrario, Alberto Alfredo
 Distribuzione geografica
Continente #
NA - Nord America 115
AS - Asia 112
EU - Europa 56
SA - Sud America 15
AF - Africa 5
Totale 303
Nazione #
US - Stati Uniti d'America 108
SG - Singapore 53
CN - Cina 24
SE - Svezia 14
IT - Italia 13
BR - Brasile 12
DE - Germania 7
FR - Francia 7
IN - India 7
VN - Vietnam 7
HK - Hong Kong 6
IE - Irlanda 4
CA - Canada 3
GB - Regno Unito 3
ID - Indonesia 3
JP - Giappone 3
AO - Angola 2
BD - Bangladesh 2
MX - Messico 2
TR - Turchia 2
AT - Austria 1
AZ - Azerbaigian 1
BE - Belgio 1
CR - Costa Rica 1
EC - Ecuador 1
ES - Italia 1
FI - Finlandia 1
IQ - Iraq 1
KE - Kenya 1
KR - Corea 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
NL - Olanda 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
TT - Trinidad e Tobago 1
UA - Ucraina 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 303
Città #
Singapore 32
Chandler 21
San Jose 14
Ashburn 10
New York 9
Beijing 8
Hong Kong 6
Frankfurt am Main 5
Dublin 4
Hyderabad 4
St Louis 4
São Paulo 4
Wilmington 4
Jakarta 3
Milan 3
Rome 3
San Mateo 3
Tokyo 3
Bari 2
Hanoi 2
Hefei 2
Ho Chi Minh City 2
Los Angeles 2
Princeton 2
Sant'Agata Bolognese 2
Washington 2
Andover 1
Ankara 1
Ann Arbor 1
Arima 1
Baghdad 1
Baku 1
Boardman 1
Buffalo 1
Cabanatuan City 1
Cabo San Lucas 1
Casablanca 1
Cattolica 1
Chisinau 1
Colombo 1
Dallas 1
Destelbergen 1
Düsseldorf 1
Elk Grove Village 1
Guayaquil 1
Helsinki 1
Houma 1
Huế 1
Ipatinga 1
Itaguara 1
Johannesburg 1
Kent 1
Kyiv 1
Lahore 1
Las Vegas 1
Lauterbourg 1
Lima region 1
Lobito 1
London 1
Luzerne 1
Macapá 1
Marseille 1
Mauá 1
Mexico City 1
Montevideo 1
Montreal 1
Mumbai 1
Nairobi 1
Niğde 1
Nuremberg 1
Porto Alegre 1
Pune 1
Rio de Janeiro 1
San José 1
Seattle 1
Seoul 1
Shanghai 1
Thái Bình 1
Tianjin 1
Toronto 1
Winnipeg 1
Woodbridge 1
Totale 212
Nome #
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large b-cell non-hodgkin lymphoma: A phase ii multicenter study of the fondazione italiana linfomi 145
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 96
Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL 69
Totale 310
Categoria #
all - tutte 1.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.620


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 1 0
2021/202220 0 0 1 2 2 0 0 4 3 0 5 3
2022/202347 6 6 2 8 1 9 1 2 7 0 5 0
2023/202428 0 7 2 1 2 7 2 0 1 0 2 4
2024/202561 0 4 6 2 6 3 0 2 10 14 10 4
2025/2026152 28 2 8 14 21 5 28 13 11 21 1 0
Totale 310